MA39250A1 - Protéines hybrides de l'interleukine-2 et leurs utilisations - Google Patents

Protéines hybrides de l'interleukine-2 et leurs utilisations

Info

Publication number
MA39250A1
MA39250A1 MA39250A MA39250A MA39250A1 MA 39250 A1 MA39250 A1 MA 39250A1 MA 39250 A MA39250 A MA 39250A MA 39250 A MA39250 A MA 39250A MA 39250 A1 MA39250 A1 MA 39250A1
Authority
MA
Morocco
Prior art keywords
proteins
relates
hybrid
interleukin
hybrid proteins
Prior art date
Application number
MA39250A
Other languages
English (en)
Other versions
MA39250B1 (fr
Inventor
Ralf Hosse
Ekkehard Moessner
Pablo Umana
Christian Klein
Laurence Bernard Peterson
Linda Wicker
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA39250A1 publication Critical patent/MA39250A1/fr
Publication of MA39250B1 publication Critical patent/MA39250B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne de manière générale des protéines hybrides d'immunoglobulines et de l'interleukine-2 (il -2). Elle concerne plus particulièrement des protéines hybrides d'immunoglobulines et d'il-2 mutante, qui présentent des propriétés améliorées permettant de les utiliser comme agents thérapeutiques, par exemple dans le traitement de maladies auto-immunes et des maladies inflammatoires à médiation immunitaire. Elle concerne en outre des polynucléotides codant pour ces protéines hybrides, ainsi que des vecteurs et des cellules hôtes comprenant ces polynucléotides. L'invention concerne également des méthodes de production des protéines hybrides de l'invention, et des méthodes d'utilisation des celles-ci dans le traitement de maladies.
MA39250A 2014-02-06 2015-02-04 Protéines hybrides de l'interleukine-2 et leurs utilisations MA39250B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461936564P 2014-02-06 2014-02-06
PCT/EP2015/052312 WO2015118016A1 (fr) 2014-02-06 2015-02-04 Protéines hybrides de l'interleukine-2 et leurs utilisations

Publications (2)

Publication Number Publication Date
MA39250A1 true MA39250A1 (fr) 2018-03-30
MA39250B1 MA39250B1 (fr) 2018-09-28

Family

ID=52669578

Family Applications (1)

Application Number Title Priority Date Filing Date
MA39250A MA39250B1 (fr) 2014-02-06 2015-02-04 Protéines hybrides de l'interleukine-2 et leurs utilisations

Country Status (32)

Country Link
US (1) US11098099B2 (fr)
EP (2) EP3102595B1 (fr)
JP (2) JP6306201B2 (fr)
KR (2) KR102042246B1 (fr)
CN (2) CN111423513A (fr)
AR (1) AR099289A1 (fr)
AU (2) AU2015215001B2 (fr)
BR (1) BR112016018288A2 (fr)
CA (1) CA2931114A1 (fr)
CL (1) CL2016001968A1 (fr)
CR (1) CR20160333A (fr)
DK (1) DK3102595T3 (fr)
EA (2) EA034350B1 (fr)
ES (1) ES2704731T3 (fr)
HR (1) HRP20190028T1 (fr)
HU (1) HUE041530T2 (fr)
IL (1) IL245484B (fr)
LT (1) LT3102595T (fr)
MA (1) MA39250B1 (fr)
MX (2) MX370283B (fr)
NZ (2) NZ719654A (fr)
PE (1) PE20161324A1 (fr)
PH (1) PH12016501406B1 (fr)
PL (1) PL3102595T3 (fr)
PT (1) PT3102595T (fr)
RS (1) RS58149B1 (fr)
SG (1) SG11201606369XA (fr)
SI (1) SI3102595T1 (fr)
TW (1) TWI671318B (fr)
UA (1) UA120847C2 (fr)
WO (1) WO2015118016A1 (fr)
ZA (1) ZA201603262B (fr)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
US20140044675A1 (en) 2012-08-10 2014-02-13 Roche Glycart Ag Interleukin-2 fusion proteins and uses thereof
PT3102595T (pt) 2014-02-06 2019-01-11 Hoffmann La Roche Proteínas de fusão de interleucina-2 e suas utilizações
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
AU2015301936B2 (en) 2014-08-11 2019-03-07 Delinia, Inc. Modified IL-2 variants that selectively activate regulatory T cells for the treatment of autoimmune diseases
HUE054935T2 (hu) 2014-12-05 2021-10-28 Aragon Pharmaceuticals Inc Rákellenes készítmények
RU2018124307A (ru) 2015-12-04 2020-01-14 Новартис Аг Антительно-цитокиновые привитые композиции и способы применения для иммунорегуляции
US10905727B2 (en) * 2016-01-14 2021-02-02 Intrexon Actobiotics N.V. Compositions and methods for the treatment of type 1 diabetes
US20170204154A1 (en) 2016-01-20 2017-07-20 Delinia, Inc. Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
RU2769282C2 (ru) 2016-06-20 2022-03-30 Кимаб Лимитед Анти-PD-L1 и IL-2 цитокины
AU2017335771A1 (en) 2016-09-28 2019-02-28 Musc Foundation For Research Development Antibodies that bind interleukin-2 and uses thereof
WO2018073365A1 (fr) 2016-10-19 2018-04-26 F. Hoffmann-La Roche Ag Procédé de production d'un immunoconjugué
EP3534947A1 (fr) 2016-11-03 2019-09-11 Kymab Limited Anticorps, combinaisons comprenant des anticorps, biomarqueurs, utilisations et procédés
EP3538548A4 (fr) * 2016-11-08 2020-08-19 Delinia, Inc. Variants d'il-2 pour le traitement de maladies auto-immunes
AU2017378308A1 (en) * 2016-12-13 2019-06-20 Delinia, Inc. Multivalent regulatory T cell modulators
EP3596108A4 (fr) 2017-03-15 2020-12-23 Pandion Operations, Inc. Immunotolérance ciblée
JOP20190271A1 (ar) * 2017-05-24 2019-11-21 Novartis Ag بروتينات مطعّمة بسيتوكين- الجسم المضاد وطرق الاستخدام للاضطرابات المتعلقة بالمناعة
MY206158A (en) 2017-05-24 2024-12-02 Novartis Ag Antibody-cytokine engrafted proteins and methods of use in the treatment of cancer
US10676516B2 (en) 2017-05-24 2020-06-09 Pandion Therapeutics, Inc. Targeted immunotolerance
KR102777151B1 (ko) 2017-11-21 2025-03-05 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 인터루킨-2의 부분 효능제
US10174092B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
USRE50550E1 (en) 2017-12-06 2025-08-26 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
EP3746103A4 (fr) 2017-12-06 2022-03-30 The Board of Trustees of the Leland Stanford Junior University Protéines modifiées pour améliorer la sensibilité d'une cellule à l'il-2
IL275426B2 (en) 2017-12-19 2025-03-01 Xencor Inc Engineered il-2 fc fusion proteins
US12247060B2 (en) 2018-01-09 2025-03-11 Marengo Therapeutics, Inc. Calreticulin binding constructs and engineered T cells for the treatment of diseases
EP3752178A1 (fr) 2018-02-16 2020-12-23 Iltoo Pharma Utilisation de l'interleukine 2 pour traiter le syndrome de sjögren
EP3765517A1 (fr) 2018-03-14 2021-01-20 Elstar Therapeutics, Inc. Molécules multifonctionnelles se liant à calréticuline et utilisations associees
PE20210313A1 (es) 2018-03-28 2021-02-12 Bristol Myers Squibb Co Proteinas de fusion interleucina-2/receptor alfa de interleucina-2 y metodos de uso
KR20250156190A (ko) 2018-06-22 2025-10-31 큐진 인크. 인터루킨-2 변이체 및 이의 사용 방법
CA3105448A1 (fr) 2018-07-03 2020-01-09 Elstar Therapeutics, Inc. Molecules d'anticorps anti-tcr et leurs utilisations
WO2020007937A1 (fr) 2018-07-03 2020-01-09 Iltoo Pharma Utilisation de l'interleukine-2 pour le traitement de la sclérose systémique
US12403181B2 (en) 2018-08-13 2025-09-02 Iltoo Pharma Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof
CA3098930A1 (fr) 2018-09-21 2020-03-26 Innovent Biologics (Suzhou) Co., Ltd. Nouvelle interleukine 2 et utilisation associee
EP3854805A4 (fr) 2018-09-21 2022-08-24 Innovent Biologics (Suzhou) Co., Ltd. Nouvelle interleukine 2 et son utilisation
SG11202106700WA (en) * 2019-01-07 2021-07-29 Inhibrx Inc Polypeptides comprising modified il-2 polypeptides and uses thereof
GB2599228B (en) 2019-02-21 2024-02-07 Marengo Therapeutics Inc Multifunctional molecules that bind to T cell related cancer cells and uses thereof
CN119039441A (zh) 2019-02-21 2024-11-29 马伦戈治疗公司 与nkp30结合的抗体分子及其用途
CN118388628A (zh) * 2019-03-29 2024-07-26 居里研究所 具有经修饰的生物活性的白介素-2变体
CN111944036B (zh) * 2019-05-14 2024-09-06 上海盖浦生物科技有限公司 一种增殖免疫细胞的突变体蛋白
BR112021023345A2 (pt) 2019-05-20 2022-02-01 Pandion Operations Inc Imunotolerância com alvo em madcam
EP3980051A4 (fr) * 2019-06-05 2023-09-13 Asher Biotherapeutics, Inc. Fusions de polypeptides d'interleukine-2 mutants avec des molécules de liaison à l'antigène pour moduler la fonction de cellules immunitaires
WO2020252421A2 (fr) * 2019-06-14 2020-12-17 Cugene, Inc. Nouveaux variants d'interleukine-2 et leurs molécules de fusion bifonctionnelles
EP3997115A4 (fr) * 2019-07-12 2023-11-22 Proviva Therapeutics (Hong Kong) Limited Compositions d'il-2 et leurs procédés d'utilisation
PH12022550165A1 (en) 2019-07-26 2023-05-08 Visterra Inc Interleukin-2 agents and uses thereof
PH12022550326A1 (en) 2019-08-13 2023-03-13 Amgen Inc Interleukin-2 muteins for the expansion of t-regulatory cells
WO2021127487A2 (fr) 2019-12-20 2021-06-24 Regeneron Pharmaceuticals, Inc. Nouveaux agonistes d'il2 et leurs procédés d'utilisation
AU2020416273A1 (en) 2020-01-03 2022-07-28 Marengo Therapeutics, Inc. Anti-TCR antibody molecules and uses thereof
US11633488B2 (en) 2020-01-10 2023-04-25 Bright Peak Therapeutics Ag Modified IL-2 polypeptides and uses thereof
WO2021146436A2 (fr) 2020-01-14 2021-07-22 Synthekine, Inc. Méthodes et compositions de mutéines d'il2 biaisées
IL295143B2 (en) 2020-02-13 2026-02-01 Hoffmann La Roche A method for determining the loading state of AAV particles using nuclear magnetic resonance relaxometry
EP4107187A4 (fr) 2020-02-21 2024-07-03 Pandion Operations, Inc. Immunotolérance ciblée sur un tissu avec un effecteur cd39
AU2021237518B2 (en) * 2020-03-19 2024-08-15 Fortvita Biologics (Singapore) Pte.Ltd. Interleukin-2 mutant and use thereof
IL298136A (en) 2020-05-13 2023-01-01 Bonum Therapeutics Inc Preparations of protein complexes and methods of using them
CN113912735B (zh) * 2020-07-08 2025-03-28 南京师范大学 多肽二聚体及其用途
WO2022050401A2 (fr) * 2020-09-01 2022-03-10 Takeda Pharmaceutical Company Limited Mutéines d'interleukine-2 et leurs utilisations
KR20230112632A (ko) 2020-10-23 2023-07-27 애셔 바이오테라퓨틱스, 인크. 면역 세포 기능을 조절하기 위한 cd8 항원 결합 분자와의 융합
JP2023548311A (ja) 2020-10-29 2023-11-16 ブリストル－マイヤーズ スクイブ カンパニー 疾患の治療のための融合タンパク質
CN112724259B (zh) * 2020-11-16 2022-12-20 天津林达生物科技有限公司 人血清白蛋白与白介素2的融合蛋白及其用途
KR20230117122A (ko) * 2020-12-04 2023-08-07 에프. 호프만-라 로슈 아게 pH 의존성 돌연변이체 인터류킨-2 폴리펩티드
US12098178B2 (en) 2020-12-04 2024-09-24 Visterra, Inc. Methods of using interleukin-2 agents
BR112023016996A2 (pt) 2021-02-24 2023-09-26 Hoffmann La Roche Métodos para purificar um polipeptídeo terapêutico e para produzir um polipeptídeo terapêutico e usos de uma solução ácida e de uma solução alcalina
CN115232215B (zh) * 2021-04-23 2026-03-27 湖州芈首生物技术有限公司 一种融合蛋白ABD/Fc/IL-2及其编码基因、制备方法和应用
IL308609A (en) 2021-05-19 2024-01-01 Asher Biotherapeutics Inc IL-21 polypeptides and target constructs
CN113789346A (zh) * 2021-08-25 2021-12-14 北京伟德杰生物科技有限公司 长效化重组人白细胞介素2融合蛋白及其制备方法和应用
CN118414160A (zh) * 2021-10-06 2024-07-30 艾尔图制药公司 对发炎组织具有靶向特异性的白介素2嵌合构建体
GB202115122D0 (en) * 2021-10-21 2021-12-08 Dualyx Nv Binding molecules targeting IL-2 receptor
EP4587043A1 (fr) 2022-09-12 2025-07-23 Institut National de la Santé et de la Recherche Médicale (INSERM) Interleukine-2 pour le traitement des troubles du spectre autistique
CN116041539B (zh) * 2022-10-31 2023-07-21 山东博安生物技术股份有限公司 Il-2突变体免疫缀合物
CN116554356B (zh) * 2023-05-16 2024-01-23 武汉大学 一种hyperIL-15与sCD4及Fc的融合蛋白及其应用

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2388385B1 (fr) 1977-04-18 1982-01-08 Hitachi Metals Ltd Piece d'ornement fixee par des aimants permanents
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
WO1985000817A1 (fr) 1983-08-10 1985-02-28 Amgen Expression microbienne de l'interleukine ii
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5650150A (en) 1990-11-09 1997-07-22 Gillies; Stephen D. Recombinant antibody cytokine fusion proteins
EP1400536A1 (fr) 1991-06-14 2004-03-24 Genentech Inc. Procédé pour fabriquer des anticorps humanisés
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
DK1034298T3 (da) 1997-12-05 2012-01-30 Scripps Research Inst Humanisering af murint antistof
HUP0100813A3 (en) 1998-02-25 2003-08-28 Lexigen Pharmaceuticals Corp L Enhancing the circulating half-life of antibody-based fusion proteins
DZ2788A1 (fr) 1998-05-15 2003-12-01 Bayer Ag Agonistes et antagonistes selectifs à IL-2.
US6955807B1 (en) * 1998-05-15 2005-10-18 Bayer Pharmaceuticals Corporation IL-2 selective agonists and antagonists
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
ES2248127T3 (es) 1999-10-04 2006-03-16 Medicago Inc. Metodo para regular la transcripcion de genes foraneos en presencia de nigtrogeno.
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
US6962696B1 (en) 1999-10-04 2005-11-08 Vion Pharmaceuticals Inc. Compositions and methods for tumor-targeted delivery of effector molecules
DK1454138T3 (da) 2001-12-04 2012-02-13 Merck Patent Gmbh Immunocytokiner med moduleret selektivitet
US7432063B2 (en) 2002-02-14 2008-10-07 Kalobios Pharmaceuticals, Inc. Methods for affinity maturation
US7569215B2 (en) 2003-07-18 2009-08-04 Massachusetts Institute Of Technology Mutant interleukin-2 (IL-2) polypeptides
US20060234205A1 (en) * 2004-03-05 2006-10-19 Chiron Corporation In vitro test system for predicting patient tolerability of therapeutic agents
EP1740615B1 (fr) 2004-03-31 2014-11-05 Genentech, Inc. Anticorps anti-tgf-beta humanises
PT1737891E (pt) 2004-04-13 2013-04-16 Hoffmann La Roche Anticorpos anti p-selectina
TWI380996B (zh) 2004-09-17 2013-01-01 Hoffmann La Roche 抗ｏｘ４０ｌ抗體
JP2008521814A (ja) 2004-11-24 2008-06-26 シェーリング コーポレイション Ｄａｐ−１０およびその使用
AU2007271398B2 (en) 2006-07-06 2013-06-20 Merck Patent Gmbh Compositions and methods for enhancing the efficacy of IL-2 mediated immune responses
JP2010534469A (ja) 2007-07-25 2010-11-11 アストラゼネカ アクチボラグ Ｋｄｒ指向性標的化結合物質およびその使用
WO2009061853A2 (fr) 2007-11-05 2009-05-14 Massachusetts Institute Of Technology Polypeptides d'interleukine-2 (il-2) mutants
AU2008343589A1 (en) 2007-12-19 2009-07-09 Centocor Ortho Biotech Inc. Design and generation of human de novo pIX phage display libraries via fusion to pIX or pVII, vectors, antibodies and methods
DE102008023820A1 (de) 2008-05-08 2009-11-12 Aicuris Gmbh & Co. Kg Mittel zur Behandlung und/oder Prophylaxe einer Autoimmunerkrankung und zur Bildung von Regulatorischen T-Zellen
AU2010206840B2 (en) * 2009-01-21 2015-02-05 Amgen Inc. Compositions and methods of treating inflammatory and autoimmune diseases
CA2806021C (fr) 2010-08-13 2019-05-21 Roche Glycart Ag Anticorps anti-fap et procedes d'utilisation
CU23923B1 (es) 2010-11-12 2013-07-31 Ct De Inmunología Molecular Polipéptidos derivados de la il-2 con actividad agonista
SG192673A1 (en) 2011-02-10 2013-09-30 Roche Glycart Ag Mutant interleukin-2 polypeptides
DK2683395T3 (en) 2011-03-11 2018-11-19 Hopitaux Paris Assist Publique USE OF LOW DOSAGE IL-2 FOR TREATMENT OF TYPE 1 DIABETES
ES2692268T5 (en) * 2011-03-29 2025-02-26 Roche Glycart Ag Antibody fc variants
EA201892619A1 (ru) * 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
EP2723380B1 (fr) * 2011-06-24 2019-08-21 Stephen D. Gillies Protéines hybrides d'immunoglobuline à chaîne légère et leurs procédés d'utilisation
US20140044675A1 (en) 2012-08-10 2014-02-13 Roche Glycart Ag Interleukin-2 fusion proteins and uses thereof
US9580486B2 (en) 2013-03-14 2017-02-28 Amgen Inc. Interleukin-2 muteins for the expansion of T-regulatory cells
PT3102595T (pt) 2014-02-06 2019-01-11 Hoffmann La Roche Proteínas de fusão de interleucina-2 e suas utilizações
MA40094B1 (fr) 2014-08-06 2022-05-31 Univ Miami Protéines de fusion de l'interleukine-2/récepteur alpha de l'interleukine-2 et procédés d'utilisation

Also Published As

Publication number Publication date
CR20160333A (es) 2016-09-05
EA201992609A1 (ru) 2020-03-04
MX2019014695A (es) 2020-02-07
PT3102595T (pt) 2019-01-11
CN105980410B (zh) 2020-02-28
AU2019264579A1 (en) 2019-12-05
HUE041530T2 (hu) 2019-05-28
US11098099B2 (en) 2021-08-24
MX2016009687A (es) 2017-03-10
SI3102595T1 (sl) 2019-02-28
PH12016501406B1 (en) 2022-04-22
AU2015215001B2 (en) 2019-08-15
KR20190126205A (ko) 2019-11-08
US20150218260A1 (en) 2015-08-06
EP3508496A1 (fr) 2019-07-10
JP6306201B2 (ja) 2018-04-04
BR112016018288A2 (pt) 2017-10-10
PH12016501406A1 (en) 2016-08-31
IL245484A0 (en) 2016-06-30
RS58149B1 (sr) 2019-02-28
AU2015215001A1 (en) 2016-05-19
CN105980410A (zh) 2016-09-28
CA2931114A1 (fr) 2015-08-13
EP3102595A1 (fr) 2016-12-14
ZA201603262B (en) 2019-10-30
CL2016001968A1 (es) 2017-02-24
WO2015118016A1 (fr) 2015-08-13
TW201534625A (zh) 2015-09-16
TWI671318B (zh) 2019-09-11
DK3102595T3 (en) 2019-02-04
UA120847C2 (uk) 2020-02-25
JP2018102312A (ja) 2018-07-05
HRP20190028T1 (hr) 2019-02-22
EP3102595B1 (fr) 2018-11-07
PL3102595T3 (pl) 2019-04-30
EA034350B1 (ru) 2020-01-30
IL245484B (en) 2019-10-31
CN111423513A (zh) 2020-07-17
LT3102595T (lt) 2019-01-25
MX370283B (es) 2019-12-09
SG11201606369XA (en) 2016-09-29
NZ760289A (en) 2023-05-26
PE20161324A1 (es) 2016-11-25
KR102042246B1 (ko) 2019-11-28
ES2704731T3 (es) 2019-03-19
JP2017510551A (ja) 2017-04-13
KR20160103134A (ko) 2016-08-31
EA201691576A1 (ru) 2016-12-30
MA39250B1 (fr) 2018-09-28
AR099289A1 (es) 2016-07-13
NZ719654A (en) 2020-06-26

Similar Documents

Publication Publication Date Title
MA39250B1 (fr) Protéines hybrides de l'interleukine-2 et leurs utilisations
MA40510A (fr) Molécules bispécifiques de liaison à l'antigène activant les lymphocytes t
CY1122306T1 (el) Συνθεσεις που περιλαμβανουν bakthpiaka στελεχη
CY1122956T1 (el) Αντισωματα εναντι αντιγονου 2 των δενδριτικων κυτταρων του αιματος και χρησεις αυτων
MA44322A (fr) Compositions comprenant des souches bactériennes
MA42471B1 (fr) Compositions comprenant des souches bactériennes
EP4597112A3 (fr) Anticorps anti-galectine-9 et leurs utilisations
MA41060B1 (fr) Compositions comprenant des souches bactériennes
MX377712B (es) Anticuerpos dirigidos contra il-33 y sus usos.
EA201491827A1 (ru) Антитела против hla-b*27 и их применение
MA41010B1 (fr) Compositions comprenant des souches bactériennes
EA201891201A1 (ru) Композиции, содержащие бактериальные штаммы
MA35448B1 (fr) Molécules bispécifiques de liaison à l'antigène activant les lymphocytes t
WO2017015622A8 (fr) Protéines de liaison à gdf11 et leurs utilisations
MX2015005384A (es) Miembros de union para il-1 beta.
MX2024001617A (es) Composiciones biofarmaceuticas.
CR20200322A (es) Anticuerpos de cadena pesada que se unen a cd22
EA201791814A1 (ru) Имидазолильные трициклические еноны как антиоксидантные модуляторы воспаления
MX361773B (es) Agentes de ligación a tlr3.
SA520420057B1 (ar) مشتقات بكساروتن واستخدامها لعلاج السرطان
BR112015011977A2 (pt) membro elétrico genérico configurável
FR3029910B1 (fr) Nouveaux composes 1-phenyl mono ou polyhydroxypropane, compositions et utilisation en cosmetique
FR3011468B1 (fr) Utilisation de l'odiparcil dans le traitement d'une mucopolysaccharidose
MA41059B1 (fr) Compositions comprenant des souches bactériennes
MA41104A (fr) Compositions comprenant des souches bactériennes